Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.
Sarki Abdulkadir, MD, PhD, has been named the winner of the 2020 Tripartite Legacy Faculty Prize in Translational Science and Education for his work investigating the molecular pathways that drive prostate cancer.
Northwestern neuroscientists and engineers have developed a tiny, implantable device that has potential to help people with bladder problems.
Men with inflammatory bowel disease have four to five times higher risk of prostate cancer, according to a new 20-year study.
Armed with a prestigious new grant, investigators prepare to rapidly translate scientific breakthroughs into better brain tumor therapies. Read the story in Northwestern Medicine magazine.
In a recent clinical trial, a drug called apalutamide added to standard therapy slowed cancer progression in men with prostate cancer, while maintaining quality of life.
An existing drug significantly lowered the risk of metastasis or death when used in men with non-metastatic castrate-resistant prostate cancer and a rising PSA level, according to a study published in the New England Journal of Medicine.
Patients with advanced prostate cancer who received more intensive treatment experienced worse quality of life at three months, but better overall in the long-term, according to a new Northwestern Medicine study.
Deputy Director Maha Hussain, MD oversees clinical research at the Lurie Cancer Center, but never forgets her primary goal: having an impact on patients.
Maha Hussain, MD, recently published several papers detailing new findings in metastatic castration-resistant prostate cancer treatment and prostate cancer screening.